Turkish Competition Authority imposed fine on Roche and Novartis.

Pursuant to the Board Decision published on the website of the Competition Authority on 13.09.2021; Novartis and Roche has violated antitrust rules by promoting and increasing the use of the more expensive ophthalmology drug, Lucentis instead of Altuzan. Therefore, an administrative fine of 112.972.552.65 TL was imposed on Roche and 165.464.716.48 TL was imposed on Novartis.

For details: https://www.rekabet.gov.tr/Dosya/geneldosya/karar_21-04-52-21-pdf